Loading
Latest filing published 14 Aug 2026 for 인바이오. Read the official filing
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
조인선, listed as chief executive, appears in our data through filings on 인바이오 shares, published by DART (FSS). Over a trading history stretching from 21 September 2022 to 14 August 2026, the count stands at 11 filings.
On the market, this insider has only ever bought: 11 purchases, €3,642 in total. The totals exclude 10 filings filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. In 2026 alone, the filings show 6 purchases and no sales.
Clusters matter here: 1 out of 4 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
The newest entry dates from 14 August 2026: an open-market purchase, in 인바이오. Filings reach the DART (FSS) feed a median of 39 days after the trade. The shorter that gap, the sooner other investors can see what insiders have done. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations